Thus, endocrine sensitivity of both normal breast cells and breast cancer cells is dynamic, raising the hypothesis that global epigenetic reprogramming of oestrogen-responsive regions of the genome can modulate endocrine sensitivity and contributes to the onset of ESR1-positive breast cancer and the acquisition of endocrine resistance. The gene discussed is ESR1; the disease is breast carcinoma.